Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning
- PMID: 17655594
- DOI: 10.1111/j.1537-2995.2007.01289.x
Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning
Abstract
Background: Delayed severe immune hemolysis due to donor-derived passenger lymphocytes is observed in minor and/or bidirectional ABO-mismatched transplants, especially after reduced-intensity conditioning (RIC). The incidence is reported in up to 30 percent of patients and can result in multiorgan failure (MOF) and death.
Study design and methods: A first group of 32 patients (historical control) underwent RIC followed by allogeneic hematopoietic peripheral blood progenitor cell transplantation at our institution. In 5 of 10 patients with a minor and/or bidirectional ABO-mismatched graft, severe immune hemolysis was observed, leading to death in 3 of them. Therefore, we initiated a protocol with prophylactic red blood cell (RBC) exchange in minor and/or bidirectional ABO mismatch of a second group of patients (study group) and investigated the incidence of hemolysis, transplant-related mortality (TRM), and overall survival (OS) and compared these data with the historical control group. Twenty-two of 80 patients in the study group had a minor and/or bidirectional ABO-mismatched donor.
Results: In 20 patients, a prophylactic RBC exchange was performed. Three patients showed mild to moderate citrate reactions, and in 1 patient the procedure had to be stopped because of hypotension. Eighteen of 20 patients engrafted uneventfully, 1 patient rejected his graft, and another 1 showed signs of mild hemolysis. In the minor and/or bidirectional ABO-mismatched setting patients in the study group had a lower risk for TRM at 1 year compared to patients in the historical control group (16% vs. 53%, p < 0.05) and a better 1-year OS (65% vs. 40%, p < 0.05).
Conclusion: RBC exchange is a safe procedure, reducing the incidence of delayed severe immune hemolysis and thus the risk of TRM in minor and/or bidirectional ABO-mismatched cases.
Similar articles
-
Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.Transfusion. 2004 Nov;44(11):1603-11. doi: 10.1111/j.1537-2995.2004.04106.x. Transfusion. 2004. PMID: 15504166
-
Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants.Transfusion. 2014 Jul;54(7):1857-63. doi: 10.1111/trf.12529. Epub 2013 Dec 24. Transfusion. 2014. PMID: 24372185
-
Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.Transfusion. 2005 Oct;45(10):1676-83. doi: 10.1111/j.1537-2995.2005.00578.x. Transfusion. 2005. PMID: 16181220 Review.
-
Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2002 Jul;30(2):87-93. doi: 10.1038/sj.bmt.1703621. Bone Marrow Transplant. 2002. PMID: 12132047
-
Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation.Curr Opin Hematol. 2007 Nov;14(6):664-70. doi: 10.1097/MOH.0b013e3282e9a576. Curr Opin Hematol. 2007. PMID: 17898572 Review.
Cited by
-
Transfusion Support for ABO-Incompatible Progenitor Cell Transplantation.Transfus Med Hemother. 2016 Jan;43(1):13-8. doi: 10.1159/000441612. Epub 2015 Oct 29. Transfus Med Hemother. 2016. PMID: 27022318 Free PMC article. Review.
-
ABO Blood Grouping Mismatch in Hematopoietic Stem Cell Transplantation and Clinical Guides.Int J Hematol Oncol Stem Cell Res. 2018 Oct 1;12(4):322-328. Int J Hematol Oncol Stem Cell Res. 2018. PMID: 30774834 Free PMC article. Review.
-
Erythrocytapheresis: Do Not Forget a Useful Therapy!Transfus Med Hemother. 2008;35(1):24-30. doi: 10.1159/000112044. Epub 2008 Jan 15. Transfus Med Hemother. 2008. PMID: 21547107 Free PMC article.
-
Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation.Front Med (Lausanne). 2020 Oct 22;7:585628. doi: 10.3389/fmed.2020.585628. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33195341 Free PMC article.
-
Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology.Transfus Med Hemother. 2019 Dec;46(6):394-406. doi: 10.1159/000503937. Epub 2019 Nov 6. Transfus Med Hemother. 2019. PMID: 31933569 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources